Smooth muscle cells (SMCs) in balloon-injured rat carotid artery express tissue-type plasminogen activator (t-PA) at a time when they are migrating from the media to the intima. Since heparin inhibits SMC migration and intimal thickening, we have examined the possibility that heparin might also inhibit t-PA expression. Heparin (nonanticoagulant fraction; molecular weight, -6,000) was administered by continuous intravenous infusion ( heparin displaces newly synthesized thrombospondin from the cell layer to the medium and thereby might interfere with thrombospondin's role as a cell cycle progression factor.6 Whether these effects of heparin are important in vivo is not known.
H eparin and related glycosaminoglycans sup- press injury-induced intimal thickening by inhibiting smooth muscle cell (SMC) proliferation and migration.1-4 Heparin also alters the kinds of matrix secreted by vascular wall cells.5-10 In ballooninjured carotid arteries of rats treated with heparin, elastin and interstitial collagen accumulation is decreased, and proteoglycan accumulation, particularly heparan sulfate proteoglycan, is increased.5 How heparin inhibits proliferation has not been determined; it is also not evident that heparin affects SMC proliferation, migration, and matrix accumulation in vivo by a common mechanism.
The migration and proliferation of cultured SMCs is also blocked by heparin.4 In some circumstances, this effect of heparin might be accounted for by a decrease in the expression of certain growth factor receptors or a decrease in the expression of oncogenes necessary for cell cycle progression.11-13 Heparin can also displace particular matrix molecules from the cell surface. Thrombospondin, for example, is expressed by SMCs; heparin displaces newly synthesized thrombospondin from the cell layer to the medium and thereby might interfere with thrombospondin's role as a cell cycle progression factor.6 Whether these effects of heparin are important in vivo is not known.
We have recently begun to investigate the possibility that heparin alters matrix deposition and inhibits SMC migration and proliferation by interfering with the expression or activity of certain enzymes required for matrix degradation.14"15 In this study, we examine the effect of heparin on plasminogen activator expression and activity in the injured rat carotid artery. SMCs in vivo and in vitro express urokinase (u-PA) and tissuetype (t-PA) plasminogen activators.14'6-19 These plasminogen activators convert plasminogen to plasmin. Plasmin in turn degrades a broad range of matrix molecules, and although it does not degrade interstitial collagens, it does activate latent collagenase. [20] [21] [22] [23] The importance of u-PA and t-PA expression for cell migration has been demonstrated for several cell types but not for SMCs. [24] [25] [26] [27] [28] [29] [30] [31] In a recent study, we demonstrated both u-PA and t-PA mRNA and activity in ballooned rat carotid artery.14 The expression of u-PA increases during the first 24 hours as SMCs enter the cell cycle; t-PA expression appears somewhat later as the cells migrate from the media to the intima. In parallel experiments in vitro, we have demonstrated that nonhuman primate SMCs express both u-PA and t-PA. 15 In particular, t-PA is induced in resting SMCs stimulated by serum or phorbol ester, and heparin inhibits this induction at the level of gene transcription. We now show that heparin decreases t-PA mRNA and the accumulation of t-PA protein and activity in the rat carotid artery after balloon injury.
Materials and Methods
Heparin (IC 1772) prepared by periodate degradation of standard heparin was provided by Drs. Marc Pascal, Jean Choay, Jean-Claude Lormeau, and Maurice Petitou of Choay Recherche, Sanofi Inc., Paris. IC 1772 is a heparin fraction (molecular weight, 6,000), which has little antithrombin activity (<10 units/mg) but possesses some anti-factor Xa activity. Reagents for the t-PA enzyme-linked immunosorbent assay (ELISA) were provided by Genentech, Inc., South San Francisco, Calif. The cDNA for rat t-PA is a 600-bp fragment kindly provided to us by Dr. J. Degen (College of Medicine, University of Cincinnati). Chondroitin-4-sulfate and standard heparin (grade II) were obtained from Sigma Chemical Co., St. Louis, Mo. All other chemicals were of reagent or molecular biological grade. Five-month-old male Sprague-Dawley rats were obtained from Simonsen, Inc., Palo Alto, Calif. Goat anti-human t-PA antibody (No. 387), human singlechain t-PA, and human Glu-plasminogen were obtained from American Diagnostica, Inc., Greenwich, Conn.
Animal Model
Rats were anesthetized, and the left carotid artery was denuded of endothelium by the passage of a 2F balloon embolectomy catheter as described previously. 32, 33 Heparin in sterile normal saline was infused intravenously by means of miniosmotic pumps (Alzet 2m12, Alza Corp., Palo Alto, Calif.) placed at the time of the carotid surgery.3,34 Controls received an intravenous infusion of saline alone. At various times after injury, the animals were killed with an overdose of pentobarbital. The arteries were flushed clear of blood with lactated Ringer's solution, removed, stripped of adventitia, frozen in liquid nitrogen, and stored at -70°C.
Morphology
Vessels for histological study were fixed by perfusion in situ with 4.0% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, at 100 mm Hg. After further immersion fixation, the vessels were dehydrated, embedded in paraffin, and cross-sectioned (6 ,um 
In Situ Hybridization
The in situ hybridization was performed as previously described with modifications.44,45 The probe specific for rat t-PA was labeled by transcription using 35S-labeled UTP (specific activity, 1,200 Ci/mmol; Amersham Corp., Arlington, Ill.). Full-length antisense and sense transcripts were used for hybridization. Specimens fixed with 4% paraformaldehyde were embedded in paraffin, sectioned, and placed on poly-D-lysine-coated slides. The sections were deparaffinized and dehydrated. They were then pretreated with proteinase K (Sigma) and prehybridized in 100 gl hybridization buffer (50% formamide, 0.3 M NaCl, 20 mM Tris [pH 8 .0], 5 mM EDTA, 0.02% polyvinylpyrrolidone, 10% dextran sulfate, and 10 mM dithiothreitol). Sections were hybridized by addition of 500,000 cpm 35S-labeled t-PA riboprobe and incubated overnight at 50°C. After hybridization, the sections were immersed in RNAase (0.02 mg/ml, Sigma) for 30 minutes at room temperature. The sections were washed further with 2x SSC followed by three 20-minute washes in 0.1 x SSC with 0.5% Tween 20 (Sigma) at 37°C. Samples were then air-dried, dipped in Kodak NTB2 nuclear emulsion, and allowed exposure for 2 weeks at 4°C. After development, the sections were stained with hematoxylin and eosin and viewed under epiluminescence to visualize the silver grains. For quantitative comparison of t-PA mRNA in arteries of heparin-treated and control arteries, the slides were hybridized, dipped, and developed at the same time. The time of development was selected so that all the grains over the media were discrete and not clumped. The number of grains over the media and the number of medial SMC nuclear profiles were counted under high-power magnification for at least two sections from each artery. The cross-sectional areas of the media and intima were measured as described previously. 33 The results are reported as both the number of grains per 100 nuclei and number of grains per square millimeter of media.
Measurement of t-PA Protein by ELISA t-PA protein was measured using an ELISA as described. 46 This assay measures free t-PA and t-PA bound by inhibitors. Addition of heparin (0-100 ,g/ml) to the assay did not affect standard t-PA recovery (data not presented).
Plasmin Generation Assay
Animals were treated with heparin or saline for 5 days after balloon catheter injury. To control for any interfering effect of heparin on the amidolytic assay of plasmin generation, 5 minutes before death control animals received 250 ,ug i.v. heparin in a volume of 0.25 ml saline. The same volume of saline was administered to animals in the heparin group. Animals were killed by intravenous injection of sodium pentobarbital and were exsanguinated by perfusion at arterial pressure with lactated Ringer's solution. After removal, the common carotid arteries were cleaned of adherent fat and connective tissue and were cut open longitudinally. Endothelium was removed from the right common carotid artery by gentle scraping with a Teflon card. Each vessel was homogenized in 1 ml ice-cold 50 mM Tris buffer, pH 9.0, and was then centrifuged at 13,000g for 5 minutes. Parallel duplicate aliquots of supernatant were incubated with a synthetic chromogenic substrate for plasmin (Spectrozyme-PL, American Diagnostica) and des-AA-fibrinogen (Desafib, American Diagnostica), in the presence and absence of both human plasminogen (Sigma) and amiloride (Sigma). These latter two reagents served to determine the plasminogen dependence and the amiloride sensitivity of the tissue amidolytic activity.40 Standard curves were constructed using human high molecular weight urokinase (Calbiochem Corp., La Jolla, Calif.) and human single-chain t-PA (American Diagnostica). The activities of u-PA and t-PA in the tissue were normalized by reference to the protein content.
Results

Effect of Nonanticoagulant Heparin (IC 1772) on Injury-Induced SMC Proliferation
In previous studies, we have shown that standard heparin inhibits intimal hyperplasia in injured arteries'`3.
To avoid difficulties with hemorrhage in these experiments, we used a low molecular weight, nonanticoagulant fraction of heparin (IC 1772). When administered for 14 days beginning at the time of left carotid balloon injury, IC 1772 (1.0 mg/kg i.v. per hour) reduced SMC accumulation (Table 1) ; it had no effect on the DNA content of the untraumatized right carotid. IC 1772 also inhibited intimal thickening (Figure 1 ).
Heparin Decreases t-PA but Not u-PA Activity in Injured Artery
As noted in our earlier study, both u-PA and t-PA activity increased in the ballooned arteries during the 14-day period after injury.14 u-PA and t-PA were pres- Table 4 ) in the heparirn-treated preparation. Arrow delineates internal elastic lamina. Bar, 10 gm. ent in normal untraumatized vessels. u-PA began to increase during the first 24 hours, whereas t-PA was not detectable immediately after balloon injury and only reappeared at 3 days (data not shown).
In heparin-treated ballooned arteries, u-PA activity was the same as in controls at 24 hours (Figure 2A ). To determine if heparin might be displacing u-PA away from the SMC surface, u-PA was measured in injured arteries extracted with Triton X-1 14. The products were phase-separated and analyzed by SDS-polyacrylamide gel electrophoresis and zymography. Membrane receptor bound u-PA of cultured macrophages has previously been shown to separate into the hydrophobic, detergent phase, whereas free u-PA and all secreted t-PA is found in the aqueous phase after phase separation.41 In extracts of normal carotid artery, all of the u-PA activity separated into the detergent phase, whereas t-PA activity was present in the aqueous phase only (data not shown). In extracts of 24-hour injured carotids, u-PA was present in both detergent and aqueous phases ( Figure 2B ). Heparin treatment did not alter this pattern of distribution.
By zymography, u-PA and t-PA activity were expressed in vessels of heparin-treated animals at 5 days after injury, and t-PA was variably diminished compared with control vessels ( Figure 2C ). These results were confirmed in quantitative assays of carotid plasmin-generating activity at 5 days. Extracts of heparintreated arteries exhibited significantly less t-PA and about the same u-PA activity as control arteries (Table  2 ). In zymograms exposed for prolonged periods of time (Figure 3 ), higher molecular weight forms of plasminogen activator could be demonstrated.47 These higher molecular weight forms represent complexes of t-PA with plasminogen activator inhibitors since the activity could be abolished with anti-t-PA antibody (data not shown); they were decreased in heparin-treated animals. antigen was measured by ELISA. The antibody used cross-reacts with rat t-PA and recognizes free t-PA and t-PA complexed with plasminogen activator inhibitor (data not shown). t-PA protein was detected at all times after injury; in agreement with the observations made by zymography, t-PA protein ( Figure 4A ) decreased immediately after injury although it was still detectable. Since t-PA protein, but not activity, was detectable at 1 day, we examined the possibility that t-PA at early times was only in t-PA/plasminogen activator inhibitor complexes. As in zymograms of 7-day samples (Figure 3 ), zymograms of 1-day samples were incubated over a longer period than usual and demonstrated a small amount of t-PA activity in high molecular weight complexes (data not shown). Heparin treatment prevented the increase in t-PA protein ( Figure 4B ).
Heparin, but not other related glycosaminoglycans, inhibits injury-induced arterial SMC proliferation in vivo and in vitro. To determine if the same specificity applied to inhibition of t-PA accumulation, we measured t-PA protein at Figure 5 ). We performed in situ hybridization studies to obtain more precise localization of t-PA expression. Histological cross sections of paraformaldehyde-fixed carotid hybridized with 35S-labeled rat t-PA riboprobe exhibited an increased number of grains over the media and intima of injured arteries as compared with uninjured arteries. Heparin treatment significantly reduced the signal over medial SMCs at 7 and 10 days ( Figure 1 , Table 4 ). Similar changes were seen in the intima at 10 days (Table 4) . Sections of vessels hybridized with "sense" t-PA riboprobes did not exhibit any increase in labeling over background. Discussion Heparin possesses several desirable attributes as a pharmacological agent for the suppression of intimal hyperplasia in traumatized arteries: It inhibits SMC proliferation and migration without retarding endothelial regeneration.334 Heparin treatment also changes the composition of the extracellular matrix in the intima. 5 The underlying molecular mechanism for these effects of heparin is unknown. To migrate and proliferate SMCs must selectively degrade the cage of pericellular matrix, and heparin might interfere with the expression or activity of certain extracellular proteases or glycosidases required for these cell functions. The plasminogen activators, t-PA and u-PA, are both expressed by SMCs in injured artery and may play a role in cell movement. '4 In this study, we demonstrate that the SMC expression of t-PA, but not u-PA, is diminished in injured arteries treated with doses of heparin sufficient to inhibit SMC proliferation, migration, and intimal thickening.
Role of Plasminogen Activators in SMC Proliferation and Migration
Although the principal function of the plasminogen activators is to regulate fibrinolysis through the generation of plasmin, they might to some extent regulate other cell functions. Plasmin can degrade many matrix proteins and, through activation of other proteases (e.g., collagenase), might influence the degradation of matrix components for which it has no activity.20-23 Tumor cells require u-PA for migration through the chorioallantoic membrane mesenchyme and human amnion2948,49 and into blood vessels. u-PA is also needed for macrophage movement and must be bound to its receptor at the cell surface.3' On the other hand, t-PA is required for follicular rupture during ovulation and for microvascular endothelial migration in amniotic membrane even though endothelial cells migrating into a wound on a plastic dish express mainly u-PA.283tt39
Our own studies of plasminogen activator expression in injured rat carotid artery show that u-PA increases during the prereplicative period (0-24 hours after injury) while t-PA decreases immediately after the endothelium is stripped off and increases several days later at a time when the SMCs are beginning to migrate from the media to the intima.'4 Both u-PA and t-PA mRNA increase in the injured vessels to a maximum at 7 days. Why medial SMCs express both plasminogen activators is not evident nor is it clear whether either plasminogen activator is required for cell function. The intimal SMCs can form a temporary luminal interface with the blood, and these luminal SMCs are not covered by thrombus. 
Heparin Inhibition of SMC Function
At present, there is no overall hypothesis to explain the various effects of heparin on SMC function. We propose that heparin might modify matrix accumulation and inhibit SMC proliferation and migration by interfering with extracellular matrix degradation. The experiments reported here provide evidence that heparin can decrease t-PA mRNA, protein, and activity in arteries 3-10 days after injury. These results might account for the inhibition of migration. Since the early u-PA accumulation is not affected by heparin, plasminogen activators are probably not involved in the inhibition by heparin of the initial wave of SMC proliferation.
Heparin might regulate plasminogen activator expression in several ways. The decrease in plasminogen activator expression might simply be because a large fraction of the SMCs are blocked in G, phase by some other mechanism so that the plasminogen activators along with other genes are not induced. However, in a cell culture model of the initial wave of proliferation, t-PA gene expression is induced by serum and phorbol ester and inhibited at the level of transcription by heparin at a time when the expression of a number of other G, genes is not affected.15 u-PA message is decreased in the presence of serum and is not affected by heparin. As in the injured artery, anticoagulant heparin and nonanticoagulant heparin fragments inhibit t-PA expression, but the related glycosaminoglycan chondroitin sulfate does not. The in vivo data reported here do not agree completely with the in vitro studies, since only t-PA protein and activity, but not t-PA mRNA, are diminished early (5 days) by heparin treatment. There are many explanations for this difference.
It is quite possible that in rat SMC heparin affects t-PA expression at the posttranscriptional as well as the transcriptional level.
Although heparin does not alter u-PA mRNA expression by SMC in vitro, it can displace cell layer-associated u-PA into the medium. 61 The in vivo experiments show a slight but statistically insignificant decrease in u-PA (Table 2) ; the amount of u-PA bound to cells (hydrophobic fraction) does not appear to be decreased. Even though total cell-associated u-PA does not seem to be affected, it is possible that heparin is interfering with the ability of the u-PA to bind plasminogen and generate plasmin. For example, heparin increases the amount of single chain (i.e., inactive) u-PA relative to two-chain (active) u-PA in endothelial cells62 and plasma clots. 63 Paradoxically, heparin increases the conversion of purified single-chain to two-chain u-PA64 and also increases the activity of both u-PA and t-PA in solution, although heparin decreases the activity of t-PA bound to fibrin.65-69 These observations suggest that heparin and related molecules might act as catalysts for plasmin generation. If cell membrane-associated heparan sulfate were to function in the same manner, then heparin might be simply disrupting the assembly of the u-PAplasminogen complex. Such a complex might require the presence of other molecules. For example, thrombospondin binds plasminogen and might be involved in the localization of plasminogen activator activity.70 Thrombospondin might also be needed for SMC proliferation.7Th72 Heparin can displace newly synthesized thrombospondin from the cell layer into the medium and thus might interfere with the formation of the plasminogen activator-plasminogen-thrombospondin complex. 6.73 Heparin might also influence the synthesis or activity of other enzymes required for the degradation of the matrix surrounding the cell. Collagenase (matrix metalloproteinase I) is induced in cultured primate SMCs by serum and is inhibited at the level of transcription by heparin.15 Secretion of major excreted protein, which is a lysosomal protease, is inhibited by heparin.74 Cultured macrophages and tumor cells express heparanase, the activity of which can be blocked by pharmacological amounts of heparin.75-78 Whether these enzymes are required for cell movement and proliferation is not known.
In summary, these in vivo data together with other in vitro observations provide support for the hypothesis that heparin may inhibit SMC function by interfering with plasminogen activator expression and activity.
